Literature DB >> 31324884

Altered chromatin recruitment by FOXA1 mutations promotes androgen independence and prostate cancer progression.

Bohan Xu1, Bing Song1, Xiaodong Lu1, Jung Kim1, Ming Hu2, Jonathan C Zhao3,4, Jindan Yu5,6,7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31324884      PMCID： PMC6796844          DOI： 10.1038/s41422-019-0204-1

Source DB:  PubMed          Journal:  Cell Res        ISSN： 1001-0602            Impact factor:   25.617


× No keyword cloud information.
  10 in total

1.  Targeting FOXA1-mediated repression of TGF-β signaling suppresses castration-resistant prostate cancer progression.

Authors:  Bing Song; Su-Hong Park; Jonathan C Zhao; Ka-Wing Fong; Shangze Li; Yongik Lee; Yeqing A Yang; Subhasree Sridhar; Xiaodong Lu; Sarki A Abdulkadir; Robert L Vessella; Colm Morrissey; Timothy M Kuzel; William Catalona; Ximing Yang; Jindan Yu
Journal:  J Clin Invest       Date:  2018-12-18       Impact factor: 14.808

2.  FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription.

Authors:  Mathieu Lupien; Jérôme Eeckhoute; Clifford A Meyer; Qianben Wang; Yong Zhang; Wei Li; Jason S Carroll; X Shirley Liu; Myles Brown
Journal:  Cell       Date:  2008-03-21       Impact factor: 41.582

3.  The initiation of liver development is dependent on Foxa transcription factors.

Authors:  Catherine S Lee; Joshua R Friedman; James T Fulmer; Klaus H Kaestner
Journal:  Nature       Date:  2005-06-16       Impact factor: 49.962

4.  Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer.

Authors:  Christopher E Barbieri; Sylvan C Baca; Michael S Lawrence; Francesca Demichelis; Mirjam Blattner; Jean-Philippe Theurillat; Thomas A White; Petar Stojanov; Eliezer Van Allen; Nicolas Stransky; Elizabeth Nickerson; Sung-Suk Chae; Gunther Boysen; Daniel Auclair; Robert C Onofrio; Kyung Park; Naoki Kitabayashi; Theresa Y MacDonald; Karen Sheikh; Terry Vuong; Candace Guiducci; Kristian Cibulskis; Andrey Sivachenko; Scott L Carter; Gordon Saksena; Douglas Voet; Wasay M Hussain; Alex H Ramos; Wendy Winckler; Michelle C Redman; Kristin Ardlie; Ashutosh K Tewari; Juan Miguel Mosquera; Niels Rupp; Peter J Wild; Holger Moch; Colm Morrissey; Peter S Nelson; Philip W Kantoff; Stacey B Gabriel; Todd R Golub; Matthew Meyerson; Eric S Lander; Gad Getz; Mark A Rubin; Levi A Garraway
Journal:  Nat Genet       Date:  2012-05-20       Impact factor: 38.330

5.  Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer.

Authors:  Qianben Wang; Wei Li; Yong Zhang; Xin Yuan; Kexin Xu; Jindan Yu; Zhong Chen; Rameen Beroukhim; Hongyun Wang; Mathieu Lupien; Tao Wu; Meredith M Regan; Clifford A Meyer; Jason S Carroll; Arjun Kumar Manrai; Olli A Jänne; Steven P Balk; Rohit Mehra; Bo Han; Arul M Chinnaiyan; Mark A Rubin; Lawrence True; Michelangelo Fiorentino; Christopher Fiore; Massimo Loda; Philip W Kantoff; X Shirley Liu; Myles Brown
Journal:  Cell       Date:  2009-07-23       Impact factor: 41.582

6.  Forkhead domain mutations in FOXA1 drive prostate cancer progression.

Authors:  Shuai Gao; Sujun Chen; Dong Han; David Barrett; Wanting Han; Musaddeque Ahmed; Susan Patalano; Jill A Macoska; Housheng Hansen He; Changmeng Cai
Journal:  Cell Res       Date:  2019-07-19       Impact factor: 25.617

7.  The landscape of long noncoding RNAs in the human transcriptome.

Authors:  Matthew K Iyer; Yashar S Niknafs; Rohit Malik; Udit Singhal; Anirban Sahu; Yasuyuki Hosono; Terrence R Barrette; John R Prensner; Joseph R Evans; Shuang Zhao; Anton Poliakov; Xuhong Cao; Saravana M Dhanasekaran; Yi-Mi Wu; Dan R Robinson; David G Beer; Felix Y Feng; Hariharan K Iyer; Arul M Chinnaiyan
Journal:  Nat Genet       Date:  2015-01-19       Impact factor: 38.330

8.  Regulation of inflammatory responses by dynamic subcellular localization of RNA-binding protein Arid5a.

Authors:  Mitsuru Higa; Masahiro Oka; Yoshitaka Fujihara; Kazuya Masuda; Yoshihiro Yoneda; Tadamitsu Kishimoto
Journal:  Proc Natl Acad Sci U S A       Date:  2018-01-22       Impact factor: 11.205

9.  Reprogramming transcription by distinct classes of enhancers functionally defined by eRNA.

Authors:  Dong Wang; Ivan Garcia-Bassets; Chris Benner; Wenbo Li; Xue Su; Yiming Zhou; Jinsong Qiu; Wen Liu; Minna U Kaikkonen; Kenneth A Ohgi; Christopher K Glass; Michael G Rosenfeld; Xiang-Dong Fu
Journal:  Nature       Date:  2011-05-15       Impact factor: 49.962

10.  Cooperativity and equilibrium with FOXA1 define the androgen receptor transcriptional program.

Authors:  Hong-Jian Jin; Jonathan C Zhao; Longtao Wu; Jung Kim; Jindan Yu
Journal:  Nat Commun       Date:  2014-05-30       Impact factor: 14.919
  10 in total
  10 in total

1.  HOXB13 suppresses de novo lipogenesis through HDAC3-mediated epigenetic reprogramming in prostate cancer.

Authors:  Xiaodong Lu; Ka-Wing Fong; Galina Gritsina; Fang Wang; Sylvan C Baca; Lourdes T Brea; Jacob E Berchuck; Sandor Spisak; Jenny Ross; Colm Morrissey; Eva Corey; Navdeep S Chandel; William J Catalona; Ximing Yang; Matthew L Freedman; Jonathan C Zhao; Jindan Yu
Journal:  Nat Genet       Date:  2022-04-25       Impact factor: 41.307

2.  FOXA2 suppresses endometrial carcinogenesis and epithelial-mesenchymal transition by regulating enhancer activity.

Authors:  Subhransu S Sahoo; Susmita G Ramanand; Yunpeng Gao; Ahmed Abbas; Ashwani Kumar; Ileana C Cuevas; Hao-Dong Li; Mitzi Aguilar; Chao Xing; Ram S Mani; Diego H Castrillon
Journal:  J Clin Invest       Date:  2022-06-15       Impact factor: 19.456

Review 3.  Shaping Chromatin States in Prostate Cancer by Pioneer Transcription Factors.

Authors:  William Hankey; Zhong Chen; Qianben Wang
Journal:  Cancer Res       Date:  2020-02-24       Impact factor: 12.701

4.  FOXA1 promotes prostate cancer angiogenesis by inducing multiple pro-angiogenic factors expression.

Authors:  Yiming Su; Yu Zhang; Jing Zhao; Wenhao Zhou; Wenhao Wang; Bangmin Han; Xiaohai Wang
Journal:  J Cancer Res Clin Oncol       Date:  2021-07-14       Impact factor: 4.553

5.  Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving 177Lu-PSMA-617 Radioligand Therapy.

Authors:  Katharina Kessel; Robert Seifert; Matthias Weckesser; Wolfgang Roll; Verena Humberg; Katrin Schlack; Martin Bögemann; Christof Bernemann; Kambiz Rahbar
Journal:  Theranostics       Date:  2020-06-18       Impact factor: 11.556

Review 6.  Pioneer of prostate cancer: past, present and the future of FOXA1.

Authors:  Mona Teng; Stanley Zhou; Changmeng Cai; Mathieu Lupien; Housheng Hansen He
Journal:  Protein Cell       Date:  2020-09-18       Impact factor: 14.870

7.  Posttranslational regulation of FOXA1 by Polycomb and BUB3/USP7 deubiquitin complex in prostate cancer.

Authors:  Su H Park; Ka-Wing Fong; Jung Kim; Fang Wang; Xiaodong Lu; Yongik Lee; Lourdes T Brea; Kristine Wadosky; Chunming Guo; Sarki A Abdulkadir; John D Crispino; Deyu Fang; Panagiotis Ntziachristos; Xin Liu; Xue Li; Yong Wan; David W Goodrich; Jonathan C Zhao; Jindan Yu
Journal:  Sci Adv       Date:  2021-04-07       Impact factor: 14.136

Review 8.  Toward a mechanistic understanding of DNA binding by forkhead transcription factors and its perturbation by pathogenic mutations.

Authors:  Shuyan Dai; Linzhi Qu; Jun Li; Yongheng Chen
Journal:  Nucleic Acids Res       Date:  2021-10-11       Impact factor: 16.971

9.  Elevated FOXA1 Expression Indicates Poor Prognosis in Liver Cancer due to Its Effects on Cell Proliferation and Metastasis.

Authors:  Zhenrong Liu; Yaru Wang; Zulihumaer Aizimuaji; Sheng Ma; Ting Xiao
Journal:  Dis Markers       Date:  2022-08-05       Impact factor: 3.464

Review 10.  Androgen Receptor Signaling in Prostate Cancer Genomic Subtypes.

Authors:  Lauren K Jillson; Gabriel A Yette; Teemu D Laajala; Wayne D Tilley; James C Costello; Scott D Cramer
Journal:  Cancers (Basel)       Date:  2021-06-30       Impact factor: 6.639
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.